AA
FDMT icon

ALPS Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

ALPS Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$706K Buy
+53,056
New +$517K ﹤0.01% 811
2025
Q2 		– Sell
-32,811
Closed -$106K – 1038
2025
Q1 		$106K Sell
32,811
-4,568
-12% -$21.5K ﹤0.01% 978
2024
Q4 		$208K Sell
37,379
-1,964
-5% -$15.4K ﹤0.01% 971
2024
Q3 		$425K Sell
39,343
-1,012
-3% -$16.8K ﹤0.01% 630
2024
Q2 		$847K Buy
40,355
+5,246
+15% +$132K 0.01% 501
2024
Q1 		$1.12M Buy
35,109
+6,077
+21% +$155K 0.01% 448
2023
Q4 		$588K Buy
+29,032
New +$382K ﹤0.01% 579
2022
Q4 		– Sell
-17,663
Closed -$142K – 1049
2022
Q3 		$142K Sell
17,663
-1,492
-8% -$13.5K ﹤0.01% 1021
2022
Q2 		$134K Buy
+19,155
New +$186K ﹤0.01% 1018

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ALPS Advisors's FDMT Position: Q2 2026 in Review

ALPS Advisors opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 53,056 shares worth $706K. The stake represents ﹤0.01% of the portfolio and ranks #811 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in FDMT as recently as Q1 2025.

ALPS Advisors first reported a position in FDMT in Q2 2022 and has held it in 9 quarters since. The position peaked at $1.12M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • ALPS Advisors held 53,056 shares of 4D Molecular Therapeutics worth $706K as of Q2 2026.
  • 4D Molecular Therapeutics was a new ALPS Advisors position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #811 holding.
  • ALPS Advisors first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • ALPS Advisors's 4D Molecular Therapeutics position peaked at $1.12M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.